IRE1 Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S7272	4μ8C	4μ8C (IRE1 Inhibitor III) is a potent and selective IRE1 Rnase inhibitor with IC50 of 76 nM.	J Integr Plant Biol, 2025, 67(9):2388-2400. J Integr Plant Biol, 2025, 10.1111/jipb.13963 Cancer Lett, 2025, 633:217993
S7771	STF-083010	STF-083010 is a specific IRE1α endonuclease inhibitor without affecting its kinase activity.	J Neuroinflammation, 2025, 22(1):38 Cell Stress Chaperones, 2025, S1355-8145(25)00010-0 Cell Death Dis, 2024, 15(8):587
S8658	kira6	kira6 is a potent type II IRE1α kinase inhibitor with an IC50 of 0.6 μM. It dose-dependently inhibits IRE1α(WT) kinase activity, XBP1 RNA cleavage, Ins2 RNA cleavage and oligomerization.	J Transl Med, 2025, 23(1):860 Sci Adv, 2025, 11(8):eadu3011 J Clin Invest, 2024, 135(1)e179874
S8286	MKC-3946	MKC3946 is a potent and soluble IRE1α endoribonuclease domain inhibitor which triggered modest growth inhibition in multiple myeloma cell lines, without toxicity in normal mononuclear cells.	PLoS One, 2024, 19(6):e0304914 Nat Commun, 2023, 14(1):2132 Int J Biol Sci, 2022, 18(3):1053-1064
S8875	MKC8866	MKC8866 (IRE1-IN-8866), a salicylaldehyde analog, is a specific IRE1α RNase inhibitor with IC50 of 0.29 μM for human IRE1α in vitro.	Cell Commun Signal, 2025, 23(1):217 EMBO Rep, 2024, 25(4):1792-1813 EMBO Rep, 2022, e51679
E2652	Kira8	Kira8 (Ire-1 inhibitor, AMG-18) is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity with an IC50 of 5.9 nM.	Cancer Commun (Lond), 2024, 10.1002/cac2.12583 Stem Cell Reports, 2024, S2213-6711(24)00006-7 bioRxiv, 2023, 2023.06.07.544081
S6623	APY29	APY29 is a type I kinase inhibitor of IRE1α that binds to the ATP-binding site on IRE1α and inhibits its autophosphorylation (IC50 = 280 nM) and enhances its RNase function (EC50 = 460 nM).	Exp Mol Med, 2022, 54(11):1927-1939
S6495	6-Bromo-2-hydroxy-3-methoxybenzaldehyde	6-Bromo-2-hydroxy-3-methoxybenzaldehyde is a bromobenzaldehyde derivative that participates in the synthesis of (±)-norannuradhapurine. This compound is an IRE-1α inhibitor with an IC50 of 0.08 μM.
S7781	Sunitinib (SU-11248)	Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. Sunitinib is also a dose-dependent inhibitor of the autophosphorylation activity of IRE1α. Sunitinib induces autophagy and apoptosis.	Cancer Cell, 2025, 43(4):776-796.e14 Mol Cancer, 2025, 24(1):179 J Exp Clin Cancer Res, 2025, 44(1):290
S1042	Sunitinib (SU11248) Malate	Sunitinib malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit. Sunitinib Malate effectively inhibits autophosphorylation of Ire1α. Sunitinib Malate increases both death receptor and mitochondrial-dependent apoptosis.	Nat Commun, 2025, 16(1):7853 CNS Neurosci Ther, 2025, 31(12):e70696 Sci Rep, 2025, 15(1):35889